Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2000-Year of the Biotechs! -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (284)	2/12/2000 3:08:00 PM
From: Jack Hartmann	Read Replies (1) \| Respond to of 1142

Doc, I don't know what research you have seen on Zadaxin. I like the sales growth in foreign countries. Also, - SciClone has exclusively sublicensed its rights to develop and market ZADAXIN in Japan to Schering-Plough K.K. However, Schering-Plough K.K. already has a substantial commitment to alpha interferon, which is an approved drug for hepatitis B and hepatitis C in Japan. - The Company is currently sponsoring clinical trials and pursuing regulatory approvals for ZADAXIN in a number of countries and it is currently sponsoring clinical trials of CPX in the United States. Of course a foreign negative clinical trial will hurt the stock as well as a negative US trial. I watch the news periodically for negative news on Zadaxin and haven't seen any. Jack